

Index

Case studies, figures, and tables are indicated by appending “c”, “f”, or “t” to the page numbers. Numbers are indexed as if spelled out. Countries are indexed only where substantive information is included in the discussion. The contents of tables are not indexed.

A

AAMI TIR 45, device software development, 348–349

AAMI TIR 57

cybersecurity evaluation process, 365

cybersecurity guidance, 370

ISO 14971 crosswalk, 366f

acceptance activities, 129

accountable care organizations (ACOs), 336

Accreditation Scheme for Conformity

Assessment (ASCA), 227

Advanced Medical Technology Association (AdvaMed)

code of ethics, 249, 256

industry/trade/professional associations, 297

regulatory convergence, 93–94, 277t

advanced therapy medicinal product (ATMP)

EU product classification, 311–313

regulatory harmonization, 316

regulatory jurisdiction, 306, 308, 309t

in US, 310–311

advertising and promotion

direct-to-customer (DTC), 253–254

global regulations for, 248–249

marketing strategy in, 225t, 250t–251t

social media, 167

through lifecycle, 95, 288

in US and EU, 249, 253–254

Africa/Middle East

harmonization efforts for, 273

medical device market, 271

regulatory agencies, 264–265t

trade organizations in, 274t

Agência Nacional de Vigilância Sanitária (ANVISA). See ANVISA

Agency for Healthcare Research and Quality (AHRQ), 11, 50

Agenzia nazionale per i servizi sanitari regionali (AGENAS), 11

Agile method software development, 346–347

agile/scrum methodology, 346–347, 347f

allogeneic use of cell/tissue products, 306, 310, 313

American National Standards Institute (ANSI)

conformity and assessment standards, 220–221, 224

Essential Requirements, 220

human factors guidance, 105

lifecycle process for software, 341

search engine for standards, 231

American Society for Testing and Materials, ASTM International. See ASTM International

International

analytical testing parameters, 165

animal studies

models for IVD assessment, 144t

purpose of, 140–142

research laws and guidance, 144t

resources for three R's, 145t

strategy for, 143f

study protocol elements, 142t

Annex Z. See ISO 14971

ANVISA

- application renewals, 201
- device registrations, 194
- implant registry, 281
- MDSAP use by, 196
- medical device manufacturer audits by, 128
- postmarketing regulatory requirements, 294
- See also Brazil*

apostille, 191**artificial intelligence (AI)**

- in medical devices, 340
- mobile medical app (MMA), 233c

Artificial Pancreas Device system, 228–229c**as low as possible (ALAP) risk, 212–213****as low as reasonably practicable (ALARP) risk, 212–213****Asia Pacific Economic Cooperation Life Sciences Innovation Forum (APEC LSIF), 15****Asian Harmonization Working Party (AHWP)**

- harmonization in, 208–209, 273
- IMDRF affiliation, 15
- intelligence resources from, 280t
- risk-based guidance, 221–222

Asia/Pacific countries

- clinical investigation requirements, 207
- country-specific information for, 249t–250t
- local variation in standards, 218
- marketing strategy in, 250t
- regulatory agencies for, 266t
- regulatory agencies in, 274t
- regulatory system focus in, 208–209, 280t

Asia-Pacific Economic Cooperation (APEC), 273**Association for Assessment and Accreditation of Laboratory Animal Care (AAALCA), 142****Association for the Advancement of Medical Instrumentation (AAMI)**

- device risk management, 364
- human factors engineering standards, 105
- ISO 13485 requirements, 224
- software standards development, 221, 341
- software validation, 342

Association of Southeast Asian Nations (ASEAN)

- IMDRF guidance use by, 294
- intelligence resources from, 280t
- IVD classifications, 168
- regulation harmonization in, 209, 273
- regulatory convergence in, 209

Association of the British Pharmaceutical Industry (ABPI), 256**ASTM International**

- device sterilization, 229c
- product standards from, 221
- resources and guidance, 236

audit processes

- ISO 19011 requirements, 72, 77, 88
- in manufacturing process, 127
- procedure requirements for internal, 77
- QMS certification and registration, 78–79
- QSR requirements, 88
- unannounced audits, 128, 214

Australia

- design transfer in, 106
- device approval duration, 194
- health economic data requirement, 11
- IMDRF membership, 15, 222
- ISO 13485 for quality requirements, 196, 292, 340
- local variation in standards, 218
- MDSAP use by, 16, 106, 196, 206
- postmarketing regulatory requirements, 293
- postmarketing regulatory strategy, 293
- primary regulatory authority, 293
- professional trade organizations, 274t
- proof of conformity, 224
- as reference market, 191
- regulatory alignment in, 342
- software regulation in, 340

Australian Register of Therapeutic Goods (ARTG)

- device listing in, 194
- device regulatory authority, 293

authorized representative

- dossier completion responsibility, 192
- local labeling requirements, 123
- submission filing and, 198–199

autologous therapy with cell/tissue products

manipulation of product and, 306, 310, 313
 point-of care autologous therapies and
 devices, 310, 312–314, 317
 testing requirements for, 314

automated tools

connection to UDI, 343
 in data systems, 350–351
 in enterprise system, 341–342
 production and quality system strategies,
 352
 regulatory information management, 354
 in software development process, 336, 353
 strategies for, 350–351, 367

See also Unique Device Identifier (UDI)

Axendia Medical Technology Globalization Report, 97–98**B**

benefit-risk analysis. *See risk-based approach*

Berne Union for the Protection of Literary and Artistic Property, 322**biocompatibility**

device classification and, 141t, 229c, 231
 guidance documents for, 229c
 ISO 10993, 135, 231
 for IVDs, 145
 in regulatory submission process, 183f
 testing for, 140t

bioinformatics, 337, 339–340**biological product deviation reports, 180****Bovine Spongiform Encephalopathy (BSE), 166–167****Bracco Diagnostics, Inc. v. Shalala, 329–330****Brazil**

device classification and testing, 184
 IMDRF membership, 15
 local variation in standards, 218
 MDSAP use by, 16, 106, 196, 206
 patent term extensions, 332
 registration renewals, 201
 regulatory alignment in, 342

See also ANVISA

Brazil Good Manufacturing Practice (BGMP), 218**Brazilian Health Regulatory Agency (ANVISA). *See ANVISA*****British Standards Institute (BSI), 220****budget impact analysis, 10–11****C****Canada**

CAN/CSA-ISO 13485:16, 219
 device classification and testing, 184
 health economic data requirement, 11
 IMDRF membership, 15, 222
 intended use and PMOA identification, 232
 ISO 13485 for quality requirements, 196,
 340
 IVD performance study requirements, 163
 MDSAP use by, 16, 106, 196, 206
 medical device regulations, 282
 patent term extensions, 332
 postmarketing regulatory requirements, 294
 postmarketing regulatory strategy, 294
 proof of conformity, 224
 reagent stability studies, 163
 as reference market, 191
 regulatory alignment in, 342
 software regulation in, 340

Canadian Agency for Drugs and Technologies in Health (CADTH), 11**Canadian Medical Device Conformity Assessment System (CMDCAS), 196****Canadian Medical Device License (MDL), 194**

CAN/CSA-ISO 13485:16. *See Canada*

case-based payment, 8**CE marking**

ISO 13485 compliance for, 70
 for IVDs, 163
 notified body (NB) requirements for, 70

CE-marked IVDs (CE-IVDs), 163**Center for Biologics Evaluation and Research (CBER)**

cloud initiative, 344
 combination product jurisdiction, 173–174,
 179
 enabling statutes for oversight, 307
 FDA jurisdictional guidance, 311
 patent application and PMOA, 329
 stem cell device regulation, 308, 309t

Center for Devices and Radiological Health (CDRH)

cloud initiative, 344
 combination product jurisdiction, 172–178,
 311
 intelligence resources from, 283t
 ISO 13485, 224

- MDSAP acceptance, 196–197
- medical device import regulation, 282
- patent application and PMOA, 328
- standard recognition process, 226–227
- stem cell device regulation, 308, 309t
- Center for Drug Evaluation and Research (CDER)**
 - cloud initiative, 344
 - combination product jurisdiction, 172–175, 177–179
 - patent application and PMOA, 329
- Center for Food and Drug Inspection (CFDI), 197**
- Center for Management of Emergency Health Surveillance Information (EVISA), 294**
- Center for Veterinary Medicine (CVM), 344**
- Centers for Medicare and Medicaid Services (CMS), 6, 50**
- Central America.** *See Latin America*
- Central Drugs Standard Control Organization (CDSCO), 16**
- Certificate of Free Sale (CFS), 191**
- certificate to foreign government (CFG), 105, 197**
- Chamber of Commerce certification, 191**
- China**
 - AdvaMed code of ethics in, 249
 - business opportunity assessment, 244c, 246c, 247
 - clinical investigation requirements, 191, 207
 - companion diagnostic device regulation, 167
 - device classification and testing, 164, 168, 184
 - device testing requirements, 153
 - GMP inspection requirement, 197
 - IMDRF membership, 15
 - inspection requirements, 197
 - local variation in standards, 218
 - patent term extensions, 332
 - postmarketing regulatory requirements, 293
 - reagent stability studies, 161, 163
 - registration requirements, 201, 271
 - regulatory alignment in, 342
 - trademark registration in, 323
 - type-testing requirement in, 194–195
- China Drug Administration (CDA), 271**
- Chinese Food and Drug Administration (CFDA).** *See National Medical Products Administration (NMPA)*
- classification of devices**
 - adult vs pediatric, 185
 - biocompatibility and, 141t, 229c, 231
 - body contact, 141t
 - global regulatory processes, 184–185
 - International Medical Device Regulators Forum (IMDRF), 167–168
 - ISO 10993 and, 139
 - of IVDs, 160–162, 167–168, 213
 - monitoring changes in, 185
 - premarket notification (510(k)) process and, 161, 192, 201, 300
 - regulatory pathway and, 184–185
 - risk-based approach and, 167–168
- CLIA (Clinical Laboratory Improvement Amendments), 162**
- Clinical and Laboratory Standards Institute (CLSI)**
 - analytical test standards, 165–166
 - guidance and standards resources, 236
 - laboratory consensus standards by, 220
- clinical claims, 150–151**
- clinical evaluation report (CER), 296**
- clinical investigations**
 - for regulatory approval, 191
 - for software, 341
 - See also ISO 14155*
- Clinical Laboratory Improvement Amendments (CLIA), 162**
- clinical strategy development, 149–156**
 - contract research organization (CRO) role, 150
 - core development team (CDT), 31–32
 - customer requirements and, 153–154
 - foreign clinical data acceptance, 153
 - investigational reimbursement, 154
 - marketing/clinical claims, 150
 - presubmission meetings in, 153
 - prioritization in, 151
 - regulatory requirements, 151–153
 - scope and responsibilities for, 149
 - site selection and enrollment, 154–155
 - for small companies, 207–208
- clinical study design**
 - clinical strategy vs., 149
 - IVDs parameters for, 164

clinical trial design

- clinical strategy vs., 149
- multiregional trials, 207–208

cloud computing, 338**cloud initiative, 344–345****coding, types of, 7****combination products, 171–182**

- adverse event reporting for, 180
- court challenge to RFD in, 177–178
- GMPs for, 179–180
- Good Manufacturing Practices (GMPs) for, 179–180
- history of OCP, 172
- investigational new drug/device (IND), 309–310
- labeling claims, 174–176
- OCP decision-making process, 176–178
- PMOA for, 17
- premarket review of, 178
- request for designation (RFD), 174–178
- strategy development for, 178–179, 181
- US labeling strategies for, 176–178
- US regulatory history of, 172
- US regulatory jurisdiction over, 172–174

commercial launches, marketing strategy for, 3–4**commercial off-the-shelf (COTS) products, 341, 349****commercial payers, in US market, 6–7****commercial product launches, 1–14**

- global marketing assessment, 3–4
- market size and competitive analysis, 4–5
- marketing analysis, 2–4
- payment pathways, 6
- regulatory considerations, 12–13
- unmet needs assessment, 4, 12–13, 243c

commercialization. See commercial product launches**Committee for Advanced Therapies (CAT), 311, 313****Committee for Electrotechnical Standardization (CENELEC), 218****Committee for Medicinal Products for Human Use (CHMP), 311****Committee of Sponsoring Organizations of the Treadway Commission, 104****Common Submission Dossier (CSDT), 107, 208–209****Common Vulnerability Scoring System (CVSS), 365****companion diagnostics (CDx), 167****competent authorities**

- Eudamed information for, 291
- European Commission Competent Authorities, 268–270t
- ISO 13485 compliance certification, 70
- licensing authority of, 316
- MEDDEV guidance development and, 298
- postmarket reporting to, 300

competitive product analysis, 4–6**complaint handling, ISO 13485 requirements, 68****consensus standard**

- development process for, 227–228
- recognized, 218
- SDO origin of, 218

consular certification, 191**contract research organization (CRO), outsourcing to, 145–147, 146t****core development team (CDT), 21–46**

- ad hoc members in, 33–34
- business development, 34
- clinical affairs representative, 31
- communications in, 35–36
- company size and, 30
- composition of, 24
- manufacturing team member, 31
- product development sequence in, 34–35
- project feasibility assessment, 21–23
- purpose and functions of, 21
- quality assurance/quality engineering, 32–33
- regulatory interactions with members, 36–42
- regulatory pathway assessment elements, 28t
- research and development (R&D) role, 29–30
- role and responsibility of, 21
- target market identification, 23
- team member involvement in lifecycle, 42, 45

Corrective and Preventive Action (CAPA)

- ISO 13485 specification of, 67–68
- manufacturing compliance for, 129–130
- in manufacturing process, 127
- in quality management, 83–84
- tracking with quality system tools and, 352

cost-benefit analysis, 10

cost-effectiveness analysis, 10
cost-minimization analysis, 10
cost-utility analysis, 10
Council Decision on Mutual Acceptance of Data (MAD), 136
country of origin (COO) requirements, 202
coverage criteria/eligibility, 8
cross-functional collaboration, CDT structure and, 22
cross-functional market access, 1–2
current Good Manufacturing Practices (CGMP), 127
Current Good Tissue Practice (CGTP), 314
Current Procedural Terminology (CPT®) codes, 8
cybersecurity, 361–372
 device hacking risks, 93
 FDA guidance for, 368–369
 guidance for, 344–345
 for instruction for use (IFU) requirements for, 367
 international guidance for, 369–370
 medical device vulnerabilities, 362
 patient safety impact of, 361–362
 personnel resources for, 363–364
 postmarket management process, 368–369
 processes for evaluation, 365
 product documentation, 367
 product security program framework, 362–363
 QMS integration of product security program for, 362
 requirements and design input, 366
 risk management, 364
 testing devices for, 366–367
 for in vitro diagnostic medical devices (IVDs), 167
 See also software
Cybersecurity and Infrastructure Security Agency (CISA), 362

D

Dansk Standards Association, 219
data accuracy and integrity, for start-up companies, 205
Declaration of Conformity
 to ISO 13485, 277, 293
 ISO 13485 acceptance in US, 224
 products in Russia, 195, 202

Denmark, DS EN ISO 13485:2016, 219
design control
 balance with risk management, 22
 ISO 13485 requirements, 24
 manufacturing compliance for, 129
 in manufacturing process, 130
 market authorization requirements, 16
 QMS/ISO 13485, 85f
 QSR and, 84, 85f
 software guidance for, 341
 for start-up companies, 205
design development
 clinical development phase, 326
 conception phase, 325–326
 patentability and freedom-to-operate search, 325–326
 preclinical phase, 326
 prototyping stage, 326
design history file (DHF)
 after transfer, 132
 for design changes, 84
 documentation for software, 349
 manufacturing compliance for, 129
 responsibilities for, 43–44t
design patents. *See patents and intellectual property*
design transfer, in manufacturing process, 130, 132
development of regulatory strategies, 15–20
device and medicinal/pharmaceutical products. *See combination products*
device classification and testing. *See classification of devices*
device design and development
 ancillary and companion products, 327
 cybersecurity in, 365
 cybersecurity testing for, 366–367
 design-arounds in, 328
 Essential Requirements in, 26, 212–213
 global environment requirements, 98
 Phase 1: requirements, 24
 Phase 2: design, 26
 Phase 3: verification and validation, 26–27
 Phase 4: commercialization, 27
 Phase 5: product maintenance, 27–29
 phases of, 25–26t
 product security program during, 362–363
 protected components of design, 327–328
 reverse engineering, 327–328

- risk management for, 93–110
 - standard use in, 228–229c, 229–231c
 - third-party patent impact on, 328–329
 - device identifier (DI), 342**
 - device master record (DMR), 27**
 - CDT manufacturing representative role, 31
 - design changes in, 28
 - responsibility for, 31, 43–44t
 - updating of contents, 129–131
 - device master records (DMR), manufacturing compliance for, 129**
 - device strategy development and implementation, 13–20**
 - combination products, 17
 - global environment, 18
 - DHR (device history record), 11**
 - labeling and packaging control, 87
 - manufacturing compliance for, 130
 - traceability and identification requirements, 85–86
 - in verification and validation (V&V), 131
 - Diagnosis Related Group (DRG), 6**
 - Digital Imaging and Communications in Medicine (DICOM), scanning/imaging standards, 221**
 - Diphoterine® Skin Wash (DSW): court challenge to RFD, 177–178**
 - direct-to-customer (DTC) advertising, 253–254**
 - distributor**
 - in approval process, 198–199
 - CDT communication with, 35
 - in-country caretaker vs., 199t, 255
 - labeling strategy requirements, 117
 - in Latin American countries, 281
 - marketing assessment and, 3
 - product registration and, 194–195
 - responsibilities of, 294
 - in submission process, 183f
 - documentation and record control**
 - document hierarchy, 223f
 - manufacturing compliance for, 129
 - dossier content**
 - content and structure of, 190–198
 - small company development of, 208
 - translation and local language for, 191–192
 - DS EN ISO 13485:2016, 219**
- E**
- electronic design history file (eDHF) system, 350**
 - electronic health record (EHS) systems, 93**
 - electronic medical record (EMR) system, 336**
 - Eli Lilly and Co. v. Medtronic, Inc., 332*
 - EN ISO 13485:2016. See European Union (EU)**
 - end-of-life documentation, 367**
 - end-of-support documentation, 367–368**
 - enterprise resource planning (ERP), 343, 352**
 - enterprise systems, 343**
 - enterprise-wide approach, automated tools and data systems, 350–351**
 - Environmental Health Risk Management, 102, 103f**
 - Essential Principles. See Essential Requirements**
 - Essential Requirements**
 - acceptance of, 220, 228, 232
 - in device development, 26, 212–213
 - standards use and, 236
 - state-of-the-art requirements for, 296–297
 - establishment inspection report (EIR), 197**
 - Establishment Licenses, 282**
 - establishment registration**
 - Chamber of Commerce certification, 191
 - for device manufacture, 128, 192
 - establishment inspection report (EIR), 194
 - FDA requirements for, 132
 - postmarket requirements for, 292
 - renewals for, 194, 201
 - in RFD, 175
 - US requirements for, 128
 - ethics**
 - AdvaMed code for, 249, 256
 - in AI-based devices, 340
 - in self-regulation of industry, 260
 - in stem cell products, 314
 - EU Medical Devices Directives (MEDDEVs). See MEDDEV guidance documents**
 - Eudamed, market surveillance and, 291**
 - European Committee for Standardization (CEN), 218**
 - European Diagnostic Manufacturers Association (EDMA, in US-EU industry trade group, 94**
 - European Free Trade Association (EFTA), 273**

European Medical Technology Industry Association (Eucomed), in US-EU industry trade group, 94

European Medicines Agency (EMA)
 combination product security, 93–94
 marketing applications for cell products, 311

European network for Health Technology Assessment (EUnetHTA), 11

European Patent Convention (EPC), 324

European Technical File, 190

European Telecommunications Standards Institute (ETSI), 218

European Union Agency for Cybersecurity (ENISA), cloud compliance strategy, 344–345

European Union (EU)

AdvaMed code of ethics in, 249
 basic market requirements, 192–194
 borderline classification of stem cell products, 313
 CE-marked IVDs (CE-IVDs), 163
 clinical investigation requirements, 191
 companion diagnostic device regulation, 167
 device classification and testing, 184
 direct-to-customer (DTC) advertising in, 253–254
 EN ISO 13485:2016, 219
 IMDRF membership, 15
 intelligence resources from, 281t
 intended use and PMOA identification, 232
 ISO 13485 for quality requirements, 196, 292, 340
 IVD definition, 157
 manufacturing QMS requirements, 127–128
 market authorization requirements, 16
 MDSAP observer status, 206
 medical device labeling, 111, 112t
 not substantially manipulated cell products, 306–307
 Outermost Regions (OMR) regulation, 273
 patent term extensions and adjustments in, 331
 postmarketing regulatory requirements, 292–293
 for postmarketing regulatory strategy, 287–288
 postmarketing regulatory strategy, 287–288
 proof of conformity, 224
 as reference market, 191

regulation as ATMPs, 306, 308, 311–313, 316
 regulatory alignment in, 342
 risk-based classification of devices, 184–185
 software regulation in, 340
 stability testing requirements, 145
 stem cell technology regulation, 311–313
 UDI-DI introduction, 343

evolutionary software development, 346

F

facility certification/inspections

animal care and research, 142
 for contract research organization (CRO), 146
 Good Clinical Practice (GCP) for cell materials, 314
 for Good Laboratory Practice (GLP) testing, 136
 Good Manufacturing Practices (GMPs) compliance, 195–197, 288
 in manufacturing process, 127–128
 by notified body (NB), 128
 terminal sterilization, 132
See also facility certification/registration

facility certification/registration. *See also establishment registration*

Failure Mode and Effect Analysis (FMEA), 295

Failure Mode Effect and Criticality Analysis (FMECA), 295

failure modes and effects analysis (FMEA), 31

Fault Tree Analysis (FTA), 295

Federal Food, Drug, and Cosmetic Act (FD&C Act), 161, 172–173, 176, 292–293, 301, 343

fee-for-service (FFS) model, 6, 8

field safety corrective actions (FSCAs), 291, 300

five-day report, 180

510(k) process. *See premarket notification (510(k)) process*

Food and Drug Administration (FDA). *See US Food and Drug Administration*

foreign manufacturer accreditation, 273

France

cybersecurity guidance from, 369
 direct-to-consumer (DTC) advertising in, 253–254

health technology assessment (HTA) in, 11
 territories regulated by, 273–274, 277
free sales certificate (FSC), 197
Fuzz Testing, 367

G

gap analysis

with design changes, 233
 in QMS implementation, 72–73

genomic sequencing, 339

Genus Medical Technologies case, 173, 179

Germany

cybersecurity guidance from, 369
 direct-to-consumer (DTC) advertising in,
 253–254
 health technology assessment (HTA) in, 11

Global Alert and Response (GAR), 294

Global Harmonization Task Force (GHTF)

device safety in Africa, 271
 dossier content guidance, 190–191
 guidance documents from, 294
 proactive postmarket surveillance, 289
 QMS guidance documents, 85, 88, 102, 271
*See also International Medical Device
 Regulators Forum (IMDRF)*

Global Medical Device Nomenclature (GMDN) database, 18

global regulatory processes, 183–204

Certificate of Free Sale (CFS), 191
 clinical evidence requirements, 190
 confirming product classification, 184
 cost vs commercial potential, 186
 country of origin (COO) requirements, 202
 data accuracy and integrity, 188–189, 189f
 data requirements for, 187–188
 design validation and clinical evidence, 191
 documentation review after submission,
 199–200
 dossier assembly and harmonization,
 190–198
 established market requirements, 192–194
 filing of submissions, 198–199
 GMPs compliance, 195–198
 legalization of documentation, 191
 linking regulatory and commercial, 185–186
 monitoring changes in classifications, 185
 planning/prioritization, 186–187, 187t
 product changes, 199–201

product development and data collection,
 190
 regional differences in classification,
 184–185
 registration renewals, 201
 regulatory regime maturity and, 198
 representatives for, 198–199, 199t
 risk and uncertainty management in, 186
 scope of, 183–184
 single vs multiple versions for market, 186
 submission process flow, 183f
 testing-based registration, 195
 third-party perspective of, 205–216
 translation and localization, 191–192
 type-testing in China and South Korea,
 194–195

global regulatory strategy (GRS)

anticipation of clinical trials, 52
 assembling the strategy, 55–56
 elements of, 54t
 environmental influences in, 52–53
 estimated review time for, 52
 market release times in, 56f
 regulatory risk addressed by, 57, 57t
 research for, 47–51
 resources for, 54
 submission requirements for, 55t
 summary presentation for, 57–58

global regulatory trade organizations, 274–277t

Good Clinical Practice (GCP)

for cellular materials, 314–315
 for clinical trial consideration, 247
 foreign clinical data acceptance, 153
 ISO 14155, 226
 for stem cell technology regulation, 314

Good Distribution Practice (GDP), certificate, 198

Good Laboratory Practice (GLP)

FDA warning letters for, 138t
 requirements for, 135–136
 for start-up companies, 205
 universal elements of, 137t

Good Manufacturing Practices (GMPs), for combination products, 179–180

Gosstandart. See GOST-R Certificate

GOST-R Certificate, 201–202

grandfathering provisions, 194, 211

Group Purchasing Organizations (GPOs), 3, 151, 242

H

harmonization

- analytical testing standards, 165–166
- European Norms (EN), 218
- of evaluation for reimbursement, 11–12
- for medical device software, 341
- software-specific standards, 349
- for stem cell technology regulation, 316

harmonized European Norms (EN), 218

Haute Autorité de Santé (HAS), 11

Hazard Analysis Critical Control Points (HACCP), 295

Hazard and Operability Study (HAZOP), 295

Health Canada (HC)

- device licenses in, 194
- MDSAP use by, 196
- significant change to device, 298
- See also Canada*

health information technology (HIT), 336–337

health risk management, framework for, 103f

health technology assessment (HTA)

harmonization, 11–12

Health Technology Assessment international (HTAi), 11

Healthcare and Public Health Sector Coordinating Councils, cybersecurity guidance, 362

Healthcare Common Procedure Coding (HCPC), 8

health-economics evaluation models, 10–11

health-related quality of life (HRQL), 10

homologous use of cell/tissue products, 306, 310, 314

hospital exemption for stem cell products, 312

hospital information systems (HIS), 336

human factors engineering (HFE)

- FDA guidance on, 105
- IEC 62366 standard and, 225
- in market analysis, 4, 243c
- in market authorization requirements, 16
- usability testing, 254
- user interface in device labeling, 118

I

ICD-10, 8

IEC 60601

- CE marking standards and, 296–297
- local variation in standards, 218

IEC 62304

- AAMI TIR 45, 348–349
- harmonized for medical device software, 341
- risk-based approach to software, 345
- SOUP definition, 349

IEC 62366

- medical device usability, 225
- product and process standards, 223
- risk management for use errors, 104–105
- sterility of device, 229

IEC 82304, software-only products, 341

IEC TR 80002, application of risk management to software, 341

IHS Market Standards Store, 163

implementation of regulatory strategies, 15–20

importer

- device tracking responsibility of, 84
- inspections of, 197
- labeling requirements for, 117, 123t
- Medical Device License (MDL) and, 194
- quality management system (QMS) for, 234
- requirements for, 294

in vitro diagnostic medical devices (IVDs), 157–170

- analytical testing requirements, 165–166
- classification and regulatory pathways, 160–162
- cybersecurity for, 167
- EU performance testing, 166
- for European Union, 163
- FDA definition/requirements, 157
- intended use or purpose for, 158–160
- IVD classification, 168
- manufacturers' pitfalls, 168
- nonclinical laboratory testing in, 144t, 145
- performance testing requirements, 164–166
- personalized medicine trends, 167
- reclassification of, 167–168
- region-specific requirements, 162
- regulatory requirements, 162
- risk classification of, 213
- target market for, 160

- in-country caretaker, 198–199**
- incremental cost-effectiveness ratio (ICER), 10**
- incremental software development, 346**
- independent registration holder, 198**
- India**
- Medical Device Rules, 16
 - reagent stability studies for, 163
 - regulation revision in, 97
 - regulatory agencies, 266t
 - regulatory barriers in, 247
 - trademark registration in, 323
- individually identifiable health information (IIHI), 361**
- information communication technology (ICT) industry, 97**
- information technology (IT). *See software***
- infrastructure as a service (IaaS), 338**
- inspection process**
- FDA inspections, 128
 - importer, 197
 - in manufacturing process, 127
 - MDSAP reports, 16
 - See also Medical Device Single Audit Program (MDSAP)*
- Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 11**
- Institute of Electrical and Electronics Engineers (IEEE), technical standards from, 221**
- Institutional Animal Care and Use Committee (IACUC), 142**
- Institutional Review Board (IRB), 131**
- instruction for use (IFU)**
- compliance for, 117–118
 - cybersecurity requirements for, 367
 - marketing strategy and, 247
 - in multiple regions, 115
 - residual risks statements in, 213
 - symbols in, 116
 - third party review, 213
- Integrating the HealthCare Enterprise (IHE), venter profiles, 344**
- intelligence resources. *See regulatory intelligence resources***
- International Accreditation Forum (IAF), guidance documents from, 72**
- International Classification of Diseases (ICD). *See ICD-10***
- International Conference on Harmonization (ICH)**
- guidance documents from, 103
 - risk management framework and models, 103–104
 - safety and efficacy standards from, 316
 - stability testing requirements, 142, 145
- International Electrotechnical Commission (IEC)**
- guidance documents from, 103
 - standard defined, 217
 - standards developed by, 220
- International Medical Device Manufacturers Association Code of Ethical Conduct (IMEDA), 254**
- International Medical Device Regulators Forum (IMDRF)**
- device regulation development and, 18
 - device regulation harmonization, 294
 - dossier content guidance on, 190–191
 - Essential Principles, 232. *See also* Essential Requirements
 - framework for risk management, 102
 - guidance documents from, 72
 - IVD classification guidelines, 167–168
 - MDSAP adoption, 16
 - medical technology sector priorities, 94
 - membership of, 15
 - objectives of, 342
 - risk-based regulatory model guidance, 222
 - software-related documents from, 342
 - table of contents for submissions, 208
- International Network of Agencies for Health Technology Assessment (INAHTA), 11**
- International Organization for Standardization (ISO)**
- framework for risk management, 102
 - guidance documents from, 103
 - intended use or purpose for IVDs, 158
 - investigation of devices for human subjects, 220
 - numbering of standards, 219
 - professional trade organizations, 276t
 - See also individual standards*
- interoperability, software security and, 344**
- invention and patent phases, 325–326**

Investigational Device Exemption (IDE)

- design validation testing, 131
- premeeting/presubmission programs, 152
- presubmission meetings in, 153

investigational medicinal product dossier (IMPD), 312**investigational new drug/device (IND)**

- clinical trial design, 179
- combination products, 309–310
- premeeting/presubmission programs, 152

ISO 9001

- ISO 13485 comparison, 59t, 60–61t, 96, 223–224
- Plan-Do-Check-Act (PDCA) process, 61
- process approach, 61–62
- QMS documentation requirements, 68
- quality management principles, 59–60

ISO 10993

- biocompatibility testing framework, 135, 139
- FDA guidance for, 231
- normative standards from, 226
- risk management and biocompatibility, 229, 235

ISO 11137, 229. *See also sterilization requirements***ISO 13485**

- AAMI TIR 45, 348–349
- adoption in different jurisdictions, 218
- audit processes, 80t–81t, 214
- audits by certification body, 79–81
- cloud compliance strategy, 345
- comparison of 2003 and 2016, 64–66t, 69t
- feedback process requirements, 68
- global applicability, 70t, 97
- harmonized for EU market, 61–63
- implementation of, 70, 71f
- ISO 9001 comparison, 59t, 60–61t
- management responsibility under, 67
- mandatory documentation level for, 68–69, 76
- manufacturing compliance for, 127–128, 130–131
- MDSAP grading system, 63–66
- model of internal audits, 63, 66–67
- QSR comparison, 66–67, 87–88
- regulatory requirements for QMS, 223–224
- resource and personnel competency, 67

- risk management process specifications, 67–68

- software design history file (DHF), 349
- software regulation, 340

See also Quality System Regulation (QSR)

ISO 14155

- clinical investigation requirements, 226
- clinical investigation standards, 223
- for clinical trial consideration, 247
- in global clinical investigation, 229c
- Good Clinical Practice (GCP), 152, 220, 223

See also Good Clinical Practice (GCP)

ISO 14971

- AAMI TIR 45, 348–349, 366f
- Annex Z changes to, 213
- application to software, 341
- in cybersecurity process, 365
- human factor assessment in, 104
- regulatory compliance demonstration, 222
- risk management for devices, 95–98, 224–225
- software design history file (DHF), 349
- validation in postmarket risk management, 296

ISO 15223, symbols in labeling, 115–117, 223, 226**ISO 19011**

- internal audits, 77
- principles of auditing, 72
- third party vs. internal audits, 88

ISO/IEC 27001, cloud compliance strategy, 345**Italy**

- direct-to-consumer (DTC) advertising in, 254
- health technology assessment (HTA) in, 11

J**Japan**

- companion diagnostic device regulation, 167
- definition of IVDs, 158
- device registration requirements, 194
- device safety surveillance, 293
- English language documents from, 273
- IMDRF membership, 15, 222
- intended use and PMOA identification, 232
- ISO 13485 for quality requirements, 196, 292

- IVD performance study requirements, 163–164
 - MDSAP use by, 16, 106, 196–197, 206
 - patent term extensions, 331
 - postmarketing regulatory requirements, 293
 - Premarket Submission for devices, 194
 - presubmission consultations in, 168
 - reagent stability studies, 163
 - as reference market, 191
 - regulatory alignment in, 342
 - stability testing requirements, 145
 - trademark registration in, 323
- K**
- key opinion leader (KOL), CDT and, 30–31**
 - Korea.** *See South Korea*
 - Korean GMPs (KGMP) requirements, 197**
- L**
- labeling requirements, 111–126**
 - country of origin, 117
 - for global marketing, 114–117
 - human factors engineering in, 118
 - instructions for use (IFU), 117–118
 - international language requirements for, 120–121
 - ISO 15223, 115–117, 223, 226
 - labeling content, 111–112, 124
 - local distributor, 117
 - local requirements for, 123
 - manufacturing compliance for, 130
 - for postmarket use control, 288
 - RFD and claims in, 177–178
 - symbol use in, 113–114
 - translations in, 117
 - UDI-DI and, 343
 - US combination products, 176–178
 - for use in multiple regions, 115f
 - Laboratory Developed Tests (LDTs), 145**
 - laboratory information management system (LIMS), 352**
 - language**
 - certification body audits, 79
 - in cross-cultural work, 263, 273
 - enterprise risk management, 104–105
 - international requirements, 120–121t
 - labeling strategies for, 120–121
 - for patent applications, 323
 - South Africa, 121t
 - symbol and foreign language on labels, 112
 - translation and local language, 117, 191–192
 - See also labeling requirements*
 - large companies**
 - core development team (CDT) in, 30–32
 - marketing claims, 151
 - outsourcing in, 145
 - quality assurance/quality engineering, 32–33
 - strategy development, 42
 - See also manufacturing processes*
 - Latin America**
 - postmarketing regulatory requirements, 293–294
 - regulatory intelligence resources, 279–281
 - learning management system (LMS), 352**
 - lifecycle**
 - CDT member involvement in, 42–44t
 - models for software, 345
 - patent maximization of, 329–330
 - phases of, 21
 - postmarketing regulatory strategy for, 287–288
 - postmarketing surveillance in, 296
 - risk management for, 95–96
 - software design activities during, 340–341
 - software development and maintenance, 336
 - software processes, 225
 - software validation during, 348–349
 - local representatives, for submission filing, 198**
- M**
- machine learning, 340**
 - management responsibility**
 - in manufacturing compliance, 128
 - QMS/ISO 13485 implementation, 71–81
 - Manufacturer and User Facility Device Experience (MAUDE) database, 290**
 - manufacturing processes, 127–134**
 - activity documentation during, 130
 - changes to marketed devices, 132–133
 - cloud compliance strategy, 345
 - cybersecurity risk management, 364
 - global regulatory process impact on, 205–216
 - information supplied by, 116t
 - ISO 13485 standards for, 127–128
 - IVD pitfalls for, 168
 - labeling requirements, 130

- management responsibility in, 128
- nonconforming products, 129. *See also*
Corrective and Preventive Action (CAPA)
- postmarketing regulatory strategy, 294
- postmarketing risk management, 296–297
- production and process control for, 129
- purchasing requirements, 129
- quality management system (QMS) in,
127–128
- Quality System Regulation (QSR) in,
127–128
- safety profile for device, 289
- software production and safety, 335–336, 345
- market access mindset, 1–2**
- market and payer landscape, reimbursement,
5**
- marketing strategy, 241–258**
 - advertising and promotion in, 225t, 248–
249, 250t–251t
 - Asia-Pacific countries, 250t
 - business opportunity assessment, 246c
 - CDT team members, 30
 - clinical investigation requirements in, 191
 - in clinical strategy development, 150
 - commercial product launches, 3–5
 - cost of regulatory approval, 246–247, 247f,
254–255
 - country-specific information for, 249t
 - direct-to-customer (DTC) advertising,
253–254
 - distribution and in-country partners, 255
 - in EU and US, 248–253, 251t
 - executive strategy for companies, 241–243
 - global market benchmarks in, 94
 - IMDRF and access to, 222
 - key concepts for, 16
 - KOL development and compliance, 254
 - Latin and South America, 252t
 - local vs global market, 206–207
 - patents and design modifications in, 326
 - prioritizing segmented targets, 245
 - product development matrix, 242t
 - regional strategy development, 243–245
 - regulatory barriers, 245, 247
 - single vs multiple versions for market, 186
 - social media and regulatory compliance,
255–257
- MDS2 form, 367**
- meaningful use (of software), 336**
- MEDDEV guidance documents**
 - compliance with current standards, 296
 - development of, 209, 298
 - on postmarket clinical follow-up, 290
- Medicaid, 6–7**
- medical apps.** *See mobile medical app (MMA)*
- medical device data systems (MDDS),
security concerns about, 93**
- Medical Device Establishment License
(MDEL), 194**
- Medical Device Reporting (FDA), 295**
- Medical Device Single Audit Program
(MDSAP)**
 - coordination of device regulations, 16
 - inspection process reports, 16
 - ISO 13485, 64–66t
 - for ISO 13485 or QSR quality system,
205–206
 - multi-jurisdictional requirements and, 106
 - participating countries, 196–197
- Medical Device Vigilance Reporting (EU),
295**
- Medical Imaging and Technology Alliance
(MITA)**
 - electrical equipment standards, 221
 - in US-EU industry trade group, 94
- Medicare, 6**
- medicinal/pharmaceutical products,
manufacturing controls for, 17**
- Medicines and Medical Devices Safety
Authority (MEDSAFE), 293**
- Member States**
 - autologous therapy requirements in, 314
 - clinical evaluation of software, 341
 - IHE profiles for, 344
 - medical device vigilance system and, 291,
294
 - oversight improvement in, 211
 - product transfer among, 311
 - trade secret law in, 323
- Mercado Común del Sur (MERCOSUR),
280**
- Middle East.** *See Africa/Middle East*
- Ministry of Food and Drug Safety (MFDS):
Korea, 194–195**
- Ministry of Health, Labour, and Welfare
(MHLW).** *See Japan; Pharmaceutical and
Medical Device Agency*

mobile medical app (MMA), 17, 93, 221, 223, 233, 337

Monitoring Project on Health Products

Marketed in Brazil, 294

Murphy's Law, 104

N

National Committee for Clinical Laboratory

Standards. *See Clinical and Laboratory Standards Institute*

National Competent Authority Report (NCAR), 291

National Electrical Manufacturers Association (NEMA, electrical equipment standards), 221

National Health Service (NHS). *See United Kingdom (UK)*

National Health Surveillance Agency (ANVISA). *See ANVISA*

National Implant Registry (INR), 281

National Institute for Health and Care Excellence (NICE), 11

National Institute of Standards and Technology, 345

National Medical Products Administration (NMPA)

medical device manufacturer audits by, 128
national product standards from, 16
postmarketing regulatory requirements, 293
product registration, 194–195
standards recognition by, 218

See also China

national regulatory authorities, effects of ISO 13485 on, 63–66

NEMA/ISO 12052, interoperability standard, 343–344

networks, 338, 344

New Zealand

medical device regulation, 293
postmarketing regulatory strategy, 293

next generation sequencing (NGS), 337, 339–340

***Ninsho* (Premarket Certification application).**

See Japan

NIST SP 800-144, cloud compliance strategy, 345

nonclinical laboratory testing, 135–148

animal studies, 140–142, 142t, 143f, 144t–145t

biocompatibility, 139–141

Good Laboratory Practice (GLP) in, 135–136

outsourcing, 145

risk management in, 136

stability testing requirements, 142, 145

in vitro diagnostics, 145

nonconforming product, 129. *See also Corrective and Preventive Action (CAPA)*

notarization, 191

notified body (NB)

CE marking and, 70

decrease in numbers of, 211

facility certification audits by, 128

review of marketed devices by, 205–206

NSSN search engine, 231

O

obsolesce of device, 326

Office of Combination Products (OCP)

court challenge to RFD, 177–178
history, 172

Office of Regulatory Affairs (ORA), 344

Office of Tissues and Advanced Therapies (OTAT), 310

off-label use, 339

off-the-shelf software, 341, 349

Oman, 271

Organization of Economic Cooperation and Development (OECD), 135

original equipment manufacturer (OEM), sourcing of, 31

Outermost Regions (OMR) of EU, 273

outsourcing

biocompatibility testing, 146

CRO selection for, 146t

device production, 132

ISO 13485 requirements, 66–67

nonclinical laboratory testing, 145–147

of sterilization processes, 127, 132–133

See also manufacturing processes

P

Pan American Health Organization (PAHO), 15

Patent Cooperation Treaty (PCT), 323–324

- patent portfolio development phases, 325–326**
- patent protection in design, 327–328**
- patent term adjustments, 330–331**
- patent term restoration, 332**
- patentability and freedom-to-operate search, 325–326**
- patents and intellectual property (IP), 321–334**
 - benefits from patents, 324–325
 - copyrights, 322
 - device and component protection, 327
 - 510(k) as infringement, 332–333
 - 510(k) as prior art, 332
 - global portfolio of, 325
 - infringement safe harbor, 332
 - invention and patent phases, 325–326
 - lifecycle maximization of, 329–330
 - patent term adjustments and extensions, 330–331
 - patent types and applications, 323
 - patentability requirements, 324
 - PMOA support by, 329
 - protected components, 327–328
 - protected components of design, 327
 - scope of, 321–322
 - support of substantial equivalence, 330
 - third-party patent impact on, 328–329
 - trade secrets, 323
 - trademarks, 322
- patient privacy protection, 337, 361**
- patient-reported outcome (PRO), 10–11**
- payment systems/pathways**
 - case-based payment, 8
 - commercial product launches, 6
 - cost control in, 1–2
 - per diem payments, 8–9
 - value of care payment model, 1–2
 - volume of care payment mode, 1–2
- Penetration Testing, 367**
- per diem payments, 8–9**
- performance testing**
 - clinical and analytical requirements, 164
 - for IVDs, 163–167
 - quality-based metrics for, 1–2
 - radio frequency (RF) performance, 338–339, 344
 - standards for, 229c
 - strategy development for, 166–167
 - for substantial equivalence, 151, 192, 207
 - variation in requirements for, 23
 - for WHO pre-qualification, 162
- Periodic safety update reports (PSUR), 300**
- personalized medicine, 159, 337**
 - machine learning role in, 340
- Pharmaceutical and Medical Device Agency (PMDA)**
 - consultations with, 168
 - MDSAP use, 197
 - Premarket Submission for devices, 194
 - regulatory guidance documents for, 273
 - See also Japan*
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), 342**
- Plan-Do-Check-Act (PDCA)**
 - cycle in QMS evolution, 77–78, 77f
 - ISO 9001 process approach, 61
 - in resource management, 62f
- platform as a service (PaaS), 338**
- point-of care autologous therapies and devices**
 - in EU, 312–313
 - in US, 310–311
- political, economic, social and technological factor (PEST) analysis, 3, 242**
- Poly Implant Prothèse breast implant scandal (PIP)**
 - Member State oversight in, 211
 - product quality changes, 248
- postmarket clinical follow-up (PMCF), regulatory transitions in EU, 209–210**
- postmarket clinical follow-up (PMCF), postmarketing surveillance, 289**
- postmarket surveillance reports (PMSR), 300**
- postmarketing 15-day alert report, 180**
- postmarketing regulatory strategy, 287–304**
 - changes after market release, 297–298
 - compliance and commercial imperatives in, 294–295
 - cybersecurity management, 363, 368
 - developing and executing of, 298–299, 301–302
 - European Union (EU) requirements, 292–293
 - IMDRF guidance documents on, 294
 - maintenance and sustaining activities, 291

- manufacturers' responsibilities, 294
 - obstacles to, 299–300
 - postmarket reporting, 300
 - postmarketing regulatory strategy, 287–288
 - proactive postmarket surveillance, 289–290
 - QMS regulatory requirements, 291–292
 - reactive vigilance in, 290–291
 - risk management in, 295–296
 - US requirements for, 288
 - See also specific countries and regions*
 - postmarketing surveillance, for stem cell technology products, 316**
 - postmarketing surveillance (PMS)**
 - GHTF device safety requirements, 289
 - for high-risk devices, 300–301
 - postmarket clinical follow-up (PMCF), 209–210, 289
 - postmarketing 15-day alert report, 180
 - proactive postmarket surveillance, 289–290
 - QMS/ISO 13485 links to, 69
 - risk management, 16, 101f
 - for stem cell products, 316
 - predicate device**
 - biocompatibility data from, 139–140
 - in clinical study design, 164, 166
 - in 510(k) process, 192, 332–333
 - substantial equivalence to, 100, 151, 192, 207
 - premarket approval (PMA) application**
 - for Class III devices, 127, 133, 161, 192, 201
 - for clinical studies, 309
 - cybersecurity in, 365–366
 - device submission pathways, 179, 261
 - documentation for, 190–191
 - guidance and resources for, 236
 - for high-risk devices, 300–301
 - information requirements for, 187–188
 - inspection process for, 196
 - intended use of device, 158
 - postmarket study requirements for, 292
 - reimbursement and, 5
 - standards use for device, 228c, 229–231c
 - supplements and amendments to, 298
 - premarket notification (510(k)) process**
 - for changes to device, 133, 234, 298, 345
 - data requirements for, 179, 207
 - device classification and, 161, 192, 201, 300
 - for established markets, 192
 - patent applications and, 332–333
 - predicate device in, 192, 332–333
 - request for designation (RFD) jurisdiction, 174–175
 - software documentation, 349
 - for substantial equivalence, 191, 259–260, 332–333
 - Prescription Medicines Code of Practice Authority (PMCPA), 256**
 - pricing, 2–3, 30, 34, 243.** *See also reimbursement*
 - primary mode of action (PMOA)**
 - cellular products, 308
 - in combination products, 17
 - intended use and, 232
 - patent application and, 328–329
 - support by patents, 329
 - process approach**
 - design control requirements, 24
 - in ISO 9001, 59–60
 - for quality management, 70
 - product development process (PDP)**
 - business plan for, 150–151
 - payment model for, 1–2
 - phase of, 34–35
 - product security program, 362–363, 363f**
 - Product Technical Requirements (PTR), 194**
 - production and process control, manufacturing compliance for, 129**
 - production identifier (PI), 342**
 - promotion.** *See advertising and promotion regulations*
 - Protected Health Information (PHI), 361**
 - prototyping stage of development, 326**
 - Public Health Service Act (PHS Act), 157, 173, 180, 307–308, 310**
 - public key infrastructure (PKI), 367**
 - purchasing.** *See supply chain management, 129*
- Q**
- QSD letter, 197**
 - quality management system (QMS), 59–92**
 - accreditation bodies for, 70
 - audit processes for certification, 74f, 76–79
 - basic process model, 61f
 - CDT assessment of, 22–23
 - certification and registration of, 78, 78t, 79f
 - certification body assessment, 80t
 - compliance requirements, 128–129
 - customization of, 88–90

- cybersecurity integration with, 362
 - defined, 58
 - design control and, 22
 - EU manufacturing requirements, 127–128
 - gap analysis for implementation, 72–73
 - global implementation of, 352
 - in-house vs external resources for, 206
 - implementation of, 71–74, 73f, 74–75
 - instruction for use (IFU), 67
 - ISO 13485 requirements for, 66, 68–69, 71–81, 85f
 - management responsibility, 302
 - in manufacturing process, 127–128
 - MDSAP use for, 196–197
 - operational assessment for, 76
 - Plan-Do-Check-Act (PDCA) for, 77–78, 77f
 - postmarketing regulatory strategy in, 287–288, 291–292
 - quality system tools, 352
 - risk-based approach in, 66–67
 - software regulation in, 340
 - system improvement in, 77, 77t
 - technical documentation for, 66–67, 74f–75f
 - third-party perspective of, 205–216
 - verification and validation (V&V) in, 67
- quality of life (QoL), 10**
- Quality System Regulation (QSR)**
- AAMI TIR 45, 348–349
 - audit processes, 88
 - CAPA system in, 83
 - CGMP compliance requirements, 128–129
 - cloud compliance strategy, 345
 - cybersecurity requirements by, 364–365
 - design control and, 84, 85f
 - documentation and record control for, 83
 - ISO 13485 comparison with, 87–88
 - ISO 14971 requirements in, 96
 - management responsibility, 82–83
 - in manufacturing process, 127–128
 - Medical Device Single Audit Program (MDSAP) for, 205–206
 - postmarketing risk management, 296
 - production and process control, 84–85
 - QMS requirements for US market, 81
 - regulation evolution, 81–82
 - software design history file (DHF)
 - documentation, 349
 - software regulation under, 340
 - supply chain management, 85
 - traceability and, 85
 - vendor quality systems, 87–88
 - See also ISO 13485; US Food and Drug Administration*
- quality-based performance metrics, 1–2**
- R**
- radio frequency (RF) performance, 338–339, 344**
- Radiological, Electromedical and Healthcare IT Industry (COCIR), 94**
- ransomware attack, 362–363**
- reagent stability study, 161, 163–164**
- recognized consensus standard, 218**
- reference laboratories: analytical testing by, 165**
- Registered Certified Body (RCB), 194**
- Regulated Product Submission (RPS), 107**
- regulatory agencies**
- Asia/Pacific countries, 266t
 - Eastern European agencies, 270t
 - European Commission Competent Authorities, 268–270t
 - Latin American, 272t
 - South Africa, 263t
- regulatory convergence**
- Advanced Medical Technology Association (AdvaMed), 93–94, 277t
 - in Association of Southeast Asian Nations (ASEAN), 209
 - for risk management/mitigation, 107
 - Summary Technical Documentation (STED), 107
- regulatory information management (RIM), 336**
- regulatory intelligence resources**
- Africa/Middle Eastern, 271, 280t
 - for animal studies, 145t
 - Asia/Pacific regulatory agencies, 271–273
 - Association of Southeast Asian Nations (ASEAN), 280t
 - blogs/discussion groups, 278t
 - from Center for Devices and Radiological Health (CDRH), 283t
 - clinical trial databases and registries, 267, 279t
 - conferences, 267

- cross-cultural negotiation skills and translation services, 263
- cybersecurity, 368–370
- Eastern European agencies, 270t
- education programs, 267, 278–279t
- EU medical device directives and guidance, 277–280
- Europe, 273
- European Commission Competent Authorities, 268–270t
- from European Union (EU), 281t
- FDA updates for, 297
- industry and trade associations, 263–267
- information management tools, 354–355
- journals/newsletters, 278t
- Latin America, 272t, 279–281, 282t
- MEDDEV documents for, 281t, 298
- meetings with regulatory agencies, 263
- North American regulatory agencies and sources, 273t, 282–284t
- personnel knowledge and training, 259–262
- professional literature and notification services, 267
- professional trade organizations, 274–277t
- for quality management system (QMS), 206
- for regulatory strategy components, 54–55
- for software best practices, 341
- software for tracking assistance, 267, 278t
- standards providers, 279t
- for standards use in regulatory strategy, 236–237
- strategic resources, 262
- third-party perspective of regulatory process, 206
- regulatory strategy components, 47–58**
 - assembling the strategy, 55–56
 - communicating the strategy, 56
 - elements of, 48t, 54t, 58
 - environmental influences, 52–53
 - gathering information, 47
 - multidisciplinary nature of, 50
 - plan elements, 37–41t
 - regulatory history, 51–52
 - regulatory risk summary, 57t
 - resources for, 54–55
 - submission requirements, 55t
 - summary presentation of, 57–58
 - target market release timelines, 56f
 - understand clinical application, 49–50
 - understanding the product, 48–49
- reimbursement**
 - coding for, 7–8
 - economic evaluations for, 11t
 - harmonization of evaluation methods, 11–12
 - health economics in, 9–10
 - investigational, 154
 - market and payer landscape, 5
 - for medical devices, 7f
 - open payments database, 248
 - payment methods, 8–9
 - premarket approval and, 5–6
 - stakeholders in, 5–6
 - US market payers, 6
 - US reimbursement coding systems, 9t
 - value of care payment model, 1–2
 - volume of care payment mode, 1–2
- Replacement Heart Valve development, 229–231c**
- request for designation (RFD)**
 - combination products, 174–176
 - stem cell technology regulation, 308, 309t
- research and development (R&D)**
 - company size and, 30
 - DMR development by, 131–132
 - role in CTD, 30
- restriction of the use of hazardous substances (RoHS), 166**
- reverse engineering, 327–328**
- risk management/mitigation**
 - animal studies for risk analysis, 141
 - application to software, 341
 - business risks, 95
 - changes in acceptability, 212–213
 - cybersecurity, 364
 - device risk sources, 22, 98, 105–107, 139t
 - elements of strategy, 16
 - failure in, 106
 - human factor assessment in, 104
 - identification and prioritization, 95
 - integrated tools for, 353
 - ISO 14971 compliance demonstration, 222
 - medical technology sector priorities, 94
 - mitigation strategy, 95
 - for multi-jurisdictional product technical files, 106
 - postmarketing regulatory strategy for, 295–296
 - postmarketing strategy, 16

- process specifications, 85f
- in product security program, 363
- regulatory convergence for, 107
- risk analysis for global marketing, 100–103, 295–296
- risk mitigation in software, 335
- safe and efficient design for, 107
- software validation during lifecycle, 348–349
- strategy for design and development, 93–110, 95t
- technological integration for, 107
- third-party anticipation of, 212
- trigger point determination, 95
- verification and validation in, 99–100
- See also risk-based approach*
- risk-based approach**
 - for cloud vendor selection and monitoring, 338–339
 - EU legislative transition, 210–211
 - hacking and off-label use of software, 339
 - ISO 13485 and QMS, 66–67
 - IVD classification and, 167–168
 - software development and maintenance, 341
 - See also risk management/mitigation*
- risk-benefit ratio**
 - ALAP vs. ALARP, 212–213
 - in clinical evaluation report (CER), 296
 - for placebo surgical procedures, 315
- Roszdrownadzor, 195, 270t**
- “router.”** *See DHR (device history record)*
- Russia**
 - device testing requirements, 153
 - GOST-R certificate renewal, 201
 - IMDRF membership, 15
 - regulatory alignment in, 342
 - testing-based registration, 195
 - trademark registration in, 323

S

- Saudi Food and Drug Authority (SFDA), 271**
- Scrum Alliance, 347.** *See also agile/scrum methodology*
- shelf-life requirements, 142, 164, 168.** *See also stability testing requirements*
- Singapore**
 - IMDRF membership, 15
 - reagent stability studies, 163
 - regulatory alignment in, 342

small companies

- advertising best practices for, 253–254
- audit functions in, 83
- clinical affairs representative, 32
- clinical strategy development, 207–208
- compliance and cost assessment, 254
- core development team (CDT) in, 30–31
- distribution control by, 202
- focus and anticipation for, 205–206
- quality assurance/quality engineering, 32–33
- quality management system (QMS), 23
- strategy development, 42
- suitable projects, 22
- team members in, 24
- See also manufacturing processes*
- social media, advertising and promotion in, 167, 255**
- software, 335–360**
 - agile/scrum methodology, 346–347, 347f
 - Artificial Intelligence (AI), 233c, 340
 - automated tools and enterprise systems, 341–342
 - cloud computing, 338–339
 - cybersecurity and data privacy, 339, 344
 - in definition of IVDs, 157–158
 - design history file (DHF) documentation for, 349
 - development and maintenance methods, 345–346
 - FDA guidance for, 17
 - functions in medical devices, 335
 - genomic sequencing, 339
 - global implementation of, 352
 - global policies and procedure strategy, 355
 - hacking and off-label use of, 339
 - in healthcare environment, 336–337
 - hybrid models for development, 347–348
 - infrastructure support tool strategy, 351–352
 - interoperability, 337, 343–344
 - ISO 13485 validation requirements, 67
 - IVD requirements for, 166
 - lifecycle of, 225
 - manufacturers strategies for, 345
 - in a medical device, 17
 - as a medical device (SaMD), 17, 343
 - mobile applications in, 338
 - networks, 338
 - open source software, 349
 - premarket cybersecurity requirements, 344

- quality system tool strategies, 352
- regulatory alignment for SaMD, 342
- regulatory framework for, 340
- regulatory information management tools, 354
- regulatory landscape for, 342
- software lifecycle management tools, 353
- strategies for automated tools, 350–351
- waterfall methodology, 346
- software as a medical device (SaMD), 17, 342**
- software as a service (SaaS), 338**
- Software Composition Analysis (SCA), 367**
- software in a medical device (SiMD), 17**
- software of unknown provenance or pedigree (SOUP), 349**
- South Africa**
 - CE marking for, 271
 - labeling requirements, 123t
 - language requirements, 121t
 - registration requirements, 271
 - regulatory agencies, 263t
- South America**
 - local variation in standards, 218
 - regulatory resources, 279–281
- South Korea**
 - GMP certificate renewal, 201
 - IMDRF membership, 15
 - manufacturing compliance for, 197
 - reagent stability studies, 163–164
 - regulatory alignment in, 342
 - type-testing requirement in, 194–195
- Spain**
 - direct-to-consumer (DTC) advertising in, 254
 - DTC advertising in, 253
- stability testing**
 - in device development, 142–143
 - IVD reagent requirements, 163–164
 - for risk management, 136
 - strategy for, 145–146
 - See also reagent stability studies*
- stakeholders.** *See third-party perspective of regulatory process*
- standards development organization (SDO)**
 - changes to standards by, 234–235
 - impartiality of, 227–228
 - importance of, 219–220
 - ISO 14971 referenced by, 225
 - for medical device industry, 219–220
 - for medical device software, 341
- Standards Task Group (STG), standard recognition process, 226**
- standards use in regulatory strategy**
 - benefits from, 226–227
 - case studies for, 228–231c, 232–233c
 - categories of, 223
 - challenges of use, 217–218
 - choosing standards for devices, 228, 231, 233–235
 - guidance and resources for, 236–237
 - numbering of standards, 218
 - organizations for global, 72
 - product standards and process standards, 223–226
 - Product Technical Requirements (PTR), 194–195
 - regulatory compliance demonstration with, 222
 - regulatory professional and development of, 235
 - standard development process, 227–228
 - use in regulatory strategy, 217–240
 - See also International Medical Device Regulators Forum (IMDRF); US Food and Drug Administration; specific standards*
- start-up companies.** *See small companies*
- State Administration of Market Regulation (SAMR), 293**
- State Food and Drug Administration (SFDA), 271**
- Static Application Security Testing (SAST), 367**
- stem cell technology regulation, 305–319**
 - clinical manufacture and distribution of, 314–315
 - clinical trials with, 315
 - EU and US regulation overlap, 305–308
 - Good Clinical Practice (GCP) for, 314
 - harmonization efforts for, 316
 - manipulation classifications and criteria for, 306–307
 - marketed products, 306t
 - postmarketing surveillance for, 316
 - public health legislation for, 305–308
 - routes in other jurisdictions, 313
- sterilization processes**
 - biocompatibility testing and, 140, 229–231
 - in manufacturing, 127

- in manufacturing process, 260–261
 - outsourcing of, 127, 132–133
 - product manipulations, 307t
 - in regulatory submission process, 183f
 - symbol use on label, 117
 - strategy development resources, 259–286**
 - substantial equivalence**
 - 510(k) for, 259–260, 332–333
 - patent support of, 330
 - to predicate device performance, 151, 192, 207
 - summary of safety and effectiveness data (SSED), 229**
 - Summary Technical Documentation (STED)**
 - global dossier, 190–191
 - regulatory convergence, 107
 - small company development of, 208
 - Sunshine Act (open payments database), 248***
 - supply chain management**
 - in core development team, 33
 - in global market, 97, 100
 - purchasing infrastructure, 3, 242
 - quality management system (QMS) for, 66–67, 224
 - responsibilities of, 34
 - UDI tracking, 112, 193
 - system-based product review, 162**
 - systems development lifecycle (SDLC), 349–350**
- T**
- Table of Contents (TOC) for Regulated Product Submission, 190–191**
 - Taiwan**
 - free sales certificate (FSC) in, 197
 - health technology assessment (HTA) in, 11
 - manufacturing compliance for, 197
 - product change reporting, 200
 - reagent stability studies, 163
 - stability studies for IVDs, 163–164
 - Taiwan Food and Drug Administration (TFDA), 197**
 - Tandvårds- och läkemedels förmånsverket (TLV), 11***
 - Tanzanian Food and Drugs Authority (TFDA), 271**
 - TEAM-NB, audits by, 211**
 - technical documentation**
 - design and development process, 67–68
 - regulatory requirements for QMS, 66–67
 - telemedicine, 337**
 - test driven development (TDD) for software, 348–349**
 - Thailand, reagent stability studies, 163**
 - The Code, 256***
 - Therapeutic Goods Administration (TGA)**
 - Asia/Pacific regulatory agencies, 266t
 - device manufacturer audits by, 128
 - IMDRF documentation acceptance, 222
 - MDSAP use by, 196
 - risk-based device classification in, 194
 - third-party authorized representative, 198–199**
 - third-party perspective of regulatory process**
 - anticipation of legislative change, 214
 - Asian regulatory system focus, 208–209
 - dossier development, 208
 - in-house vs external resources, 206
 - planning for legislative change, 211–212
 - regulatory transitions, 209–210
 - risk classification of IVDs, 213
 - risk management for, 211–213
 - unannounced audits, 214
 - third-party perspective of regulatory process**
 - clinical data collection, 207
 - European Union (EU) marketing, 205–206
 - file format for submissions, 208
 - market entry strategy, 206–207
 - 30-day malfunction report, 180**
 - threat modeling, 362–363**
 - three-day field alert report, 180**
 - Todokede (Premarket Submission). See Japan***
 - total addressable market (TAM), 4**
 - traceability**
 - ISO 13485 requirements, 68–69
 - manufacturing compliance for, 129
 - Transatlantic Economic Council (TEC), 94**
 - transparency**
 - AI-based device use and, 340
 - in clinical trial strategies, 207
 - Eudamed and market surveillance, 291
 - of market surveillance, 301
 - OCP jurisdiction assignments, 176
 - physician payments and, 254
 - for provider reimbursement, 154
 - in regulatory regimes, 198

- in regulatory strategy development, 16, 18
 - software use and, 351
 - “traveler.”** *See DHR (device history record)*
 - Tuckman, Bruce, 34**
 - 21 CFR Part 820.** *See Quality System Regulation (QSR)*
 - Tylenol recall (Johnson and Johnson), 302**
 - type-testing requirements**
 - in China and South Korea, 194–195
 - for global business opportunity, 246c
- U**
- UDI-DI, 343**
 - unannounced audits, 128**
 - Underwriters Laboratories (UL)**
 - electrical safety standards, 105, 226
 - guidance and resources from, 236, 370
 - technical standards by, 220–221
 - Unique Device Identifier (UDI)**
 - guidance from China, 271
 - implementation of, 18
 - ISO 13485 specification of, 68
 - labeling regulations for, 341
 - in labeling strategy, 111–113, 114f
 - software-related documents from, 342
 - use in Asian systems, 208–209
 - See also automated tools*
 - United Kingdom (UK)**
 - APBI *Code of Practice* in, 256
 - direct-to-consumer (DTC) advertising* in, 253–254
 - EU withdrawal effects, 15, 312, 317
 - health technology assessment (HTA) in, 11
 - human cell and tissue regulation in, 312
 - ISO representation in, 220
 - ransomware attack cost, 362
 - regulation of Latin American territories, 273
 - United States Pharmacopoeial Convention (USP), 142**
 - United States (US)**
 - AdvaMed code of ethics in, 249
 - basic market requirements, 192
 - CLIA categorization of IVDs, 162
 - cybersecurity vulnerabilities for devices, 362
 - device classification and testing, 184–185
 - GMP compliance, 196–197
 - IMDRF membership, 222
 - ISO 13485 acceptance in US, 224
 - MDSAP use by, 16, 106, 196–197, 206
 - medical device labeling, 111, 113t
 - medical device regulations, 282
 - minimally manipulated cell products, 306
 - patent eligibility in, 324
 - patent term extensions and adjustments in, 330–331
 - payers in market, 6–7
 - physician payments in, 248, 254
 - point-of care autologous therapies, 310
 - postmarketing regulatory requirements, 288, 292
 - Quality System Regulation (QSR) in, 15
 - as reference market, 191
 - regulatory alignment in, 342
 - reimbursement coding systems in, 9t
 - stability testing requirements, 145
 - standard recognition process in, 218, 226–227
 - trademark registration in, 323
 - Universal Copyright Convention (UCC), 322**
 - unmet needs assessment, 4, 12–13, 243c**
 - US Food and Drug Administration (FDA)**
 - cloud initiative, 344–345
 - combination product and device definition, 17
 - combination product security, 93–94
 - combination products definitions, 171–176
 - companion diagnostic devices, 167
 - cybersecurity guidance, 344, 362, 368–369
 - cybersecurity in premarket submissions, 367
 - design transfer and QSR, 105–106
 - effects of ISO 13485 on, 63–66
 - guidance documents from, 72
 - guidance on ISO 14971, 222
 - high-risk software function regulation by, 343
 - internet and social media platform guidance, 257–258
 - IVD definition by, 157
 - IVD performance study requirements, 166–167
 - medical device software issues, 353–354
 - medical product risk management, 102f
 - pre- and postmarket product risk management, 101f
 - preapproval inspections, 127–128
 - premeeting/presubmission programs, 152
 - QSR and ISO 13485 alignment, 15, 96
 - Quality System Regulation (QSR), 81–87

- recognized consensus standard, 218
 - social media advertising guidance, 167
 - software and device guidance, 17
 - software in device recalls, 335
 - stem cell technology regulation, 308–311
 - submission of standard for recognition, 235
 - See also Quality System Regulation (QSR); United States (US)*
 - US National Research Council, risk management framework for public health, 101–102**
 - US Patent and Trademark Office (USPTO), 322–323**
 - US Technical Advisory Groups (TAGs), 220**
 - usability.** *See human factors engineering (HFE)*
 - utility patents, 323**
- V**
- validation.** *See verification and validation (V&V)*
 - value of care payment model, 1–2**
 - verification and validation (V&V)**
 - activities for design verification, 130–132
 - automated tool validation, 341–342
 - cybersecurity, 367
 - DHR (device history record) for, 131
 - for global marketing, 99
 - ISO 13485 requirements, 67
 - in manufacturing process, 130, 132
 - in quality management system (QMS), 67
 - in regulatory submission process, 183f
 - software validation during lifecycle, 348–349
 - software validation guidance, 341
 - vigilance system, 290–291**
 - volume of care payment mode, 1–2**
 - vulnerability**
 - device testing for, 367
 - identified in devices, 368
 - ransomware attack, 362–363
 - Vulnerability Disclosure (cybersecurity), 368**
 - Vulnerability Scanning, 367**
- W**
- WannaCry Ransomware attack, 362**
 - waterfall software development method, 346**
 - Web Application Security Testing, 367**
 - Web Assisted Notification of Devices (WAND) database, 293**
 - World Health Organization (WHO)**
 - device pre-qualification process, 164
 - Global Alert and Response (GAR), 294
 - IMDRF observer status, 15
 - MDSAP observer status, 206
 - pre-qualification performance testing, 162
- Z**
- Zorginstituut Nederland (ZIN), 11**